Replies to post #14164 on RespireRx Pharmaceuticals Inc (fka RSPI)

[davidal66]

gfp, to be a Cortex shareholder, you must see some positive scenario that will bring the stock price up: the stock is undervalued. This does not mean the rosy scenario is right, but if one has a truly bearish scenario, why own the stock? even at 49 cents? I have typically gotten too bullish with Cortex, but I think that 2-4 dollars with just a bit of good news is realistic. I think Cortex is a compelling buy at 49 cents and have added to my position here; that doesn't make me right.

In the short term, I can see several distinct positive scenarios:

1. Schering partnership for additional ampakines, possibly expanding applications to include RD. That would turn us into a 2-4 bagger in a minute. It would also lower cash needs since CX701 et al would be under the development of another pharma.

2. RD news showing a biologically significant reversal of resp. depression with CX717 in the acute setting... a new indication with an acute usage for CX717.

3. PET scan study results later in '08.

I'm not talking about a 50 dollar stuck, but if one or more of these events click, the stock price will, IMHO, soar to 2-4 dollar range.

[neuroinv]

When you develop a sober and balanced perspective, post something to show it.

The discussion on this Board has been deteriorating. With a few exceptions, there is far too much kvetching and complaining, like a bunch of caffeinated housewives with too much time on their hands. There is plenty of genuine uncertainty, which is addressed on intermittent occasion: Is the RD indication for real, with real potential value? Is the trial design one which is likely to work, and if it doesn't, what then? To what degree are Ampakines as a class viewed negatively by the FDA--or not? What will Schering-Plough do? What are the industry trends for partnerships and indications, and what do they augur for Cortex, if anything? How much clout does R&R have in trying to force a sale on the cheap?

Those are just a few examples. Substantive interchange could have been had, and I am not talking about rosy spin--in fact, it is ironic that Gfp, who self-righteously complains that I spin, has been at times a most promiscuous "slam dunk" pollyanna. Yowling that management must buy 'millions' of dollars of stock to be taken seriously, or hyping a Lilly abstract that, if read with any care, deserves attention but not adulation; or paranoid blather about "scams"--that kind of claptrap is a waste of time, time I am disinclined to give.

NeuroInvestment